Stock Events

Stock Events

Annovis Bio 

€1.91
55
+€0.12+6.7% Wednesday 06:09

Statistics

Day High
1.79
Day Low
1.76
52W High
4.61
52W Low
1.07
Volume
2,155
Avg. Volume
-
Mkt Cap
50.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.97
-0.74
-0.5
-0.27
Expected EPS
-0.4
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-46.44MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 07X.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, directly competing with Annovis Bio's Alzheimer's and Parkinson's disease treatments.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Annovis Bio.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Acadia Pharmaceuticals targets central nervous system disorders including Parkinson's disease, competing with Annovis Bio.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. works on developing treatments for Alzheimer's disease, directly competing with Annovis Bio.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics develops novel therapies for central nervous system disorders, including Alzheimer's, making it a competitor.
Prothena
PRTA
Mkt Cap578.67M
Prothena Corporation plc focuses on the development of treatments for neurodegenerative diseases, competing in the same space as Annovis Bio.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals develops RNAi therapeutics for neurodegenerative diseases, positioning it as a competitor to Annovis Bio.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery for neurodegenerative diseases, making it a competitor.

About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Show more...
CEO
Dr. Maria L. Maccecchini Ph.D.
Employees
8
Country
US
ISIN
US03615A1088
WKN
000A2PNH2

Listings

XNYS
US
ANVS
F
DE
07X.F
BOATS
BOATS
ANVS.BOATS

0 Comments

Share your thoughts

FAQ

What is Annovis Bio stock price today?▼
The current price of 07X.F is €1.91 EUR — it has increased by +6.7% in the past 24 hours. Watch Annovis Bio stock price performance more closely on the chart.
What is Annovis Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Annovis Bio stocks are traded under the ticker 07X.F.
Is Annovis Bio stock price growing?▼
07X.F stock has risen by +0.42% compared to the previous week, the month change is a -14.35% fall, over the last year Annovis Bio has showed a +40.44% increase.
What is Annovis Bio market cap?▼
Today Annovis Bio has the market capitalization of 50.62M
When is the next Annovis Bio earnings date?▼
Annovis Bio is going to release the next earnings report on May 19, 2026.
What were Annovis Bio earnings last quarter?▼
07X.F earnings for the last quarter are -0.34 EUR per share, whereas the estimation was -0.27 EUR resulting in a -26.46% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Annovis Bio revenue for the last year?▼
Annovis Bio revenue for the last year amounts to 0 EUR.
What is Annovis Bio net income for the last year?▼
07X.F net income for the last year is -46.44M EUR.
How many employees does Annovis Bio have?▼
As of April 02, 2026, the company has 8 employees.
In which sector is Annovis Bio located?▼
Annovis Bio operates in the Health Care sector.
When did Annovis Bio complete a stock split?▼
Annovis Bio has not had any recent stock splits.
Where is Annovis Bio headquartered?▼
Annovis Bio is headquartered in Malvern, US.